1. Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives
   Lisa Lellouche et al, 2021, Therapeutic Advances in Medical Oncology CrossRef
2. Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer
   Jeung Eun Lee et al, 2020, Gut and Liver CrossRef
3. The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective study
   Hyun yeb Jung et al, 2022, Journal of Yeungnam Medical Science CrossRef
4. Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
   Daniel M. Girardi et al, 2019, Journal of Gastrointestinal Cancer CrossRef
5. Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis
   Kotone Hayuka et al, 2021, Chemotherapy CrossRef
6. The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer
   Merel J.M. van Velzen et al, 2021, European Journal of Cancer CrossRef
7. Pancreatic adenocarcinoma: Beyond first line, where are we?
   Sara Cherri et al, 2021, World Journal of Gastroenterology CrossRef
8. Chemotherapy for pancreatic cancer
   Christoph Springfeld et al, 2019, La Presse Médicale CrossRef
9. Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives (Review)
   Leonel Pekarek et al, 2021, Oncology Letters CrossRef
10. Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models
    Chrysovalantou Mihailidou et al, 2018, Oncotarget CrossRef
11. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
    Heejung Chae et al, 2020, Therapeutic Advances in Medical Oncology CrossRef
12. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study
    Sonia Zaibet et al, 2022, British Journal of Cancer CrossRef
13. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation
    Yung-Yeh Su et al, 2023, Biomedical Journal CrossRef
14. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study
    Julien Taieb et al, 2020, ESMO Open CrossRef
15. Systemic Therapies for Pancreatic Cancer
    Faysal Dane et al, 2022, The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases CrossRef
16. Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece
    George Papaxoinis et al, 2020, Journal of Oncology CrossRef
17. Large-Scale Machine Learning Analysis Reveals DNA Methylation and Gene Expression Response Signatures for Gemcitabine-Treated Pancreatic Cancer
    Adeolu Ogunleye et al, 2024, Health Data Science CrossRef
18. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
    Naoki Mita et al, 2019, Journal of Clinical Medicine CrossRef
19. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial
    Pascal Hammel et al, 2020, European Journal of Cancer CrossRef